Lip augmentation and contour correction with a ribose cross-linked collagen dermal filler.
BACKGROUND
Dermicol-P35 is a collagen gel for soft-tissue cosmetic correction. This study evaluated the affects of Dermicol-P35 in patients who underwent lip enhancement.


METHODS
This open, multicenter, retrospective data collection study included patients who received an injection of Dermicol-P35 30G to the lip. All patients who had undergone Dermicol-P35 30G lip injections at 3 cosmetic clinics in Europe were identified and evaluated for inclusion in the study. Assessments were conducted by a clinic investigator immediately after the initial injections and after any touch-up injections as well as 4 months to 10 months after the initial injection. Efficacy measures included subjective impression of improvement by the clinic investigator who performed the injections, and subjective satisfaction of both the investigator and patient with treatment. Safety measures included any adverse events, and the occurrence of swelling, bruising, lumpiness, and pain.


RESULTS
Fifty-seven patients were identified to have undergone lip injections, and 51 of these patients met criteria for inclusion in the study. Four months to 10 months postinjection, most patients (98%) were believed to have an improvement in lip enhancement, and the clinic investigators rated themselves as "very satisfied" or "satisfied" with 90% of the treatment results. The majority of patients (94%) were either "very satisfied" or "satisfied" with the Dermicol-P35 30G enhancement. The majority of treatments elicited no reports of swelling, bruising, or lumpiness.


CONCLUSIONS
These study results support Dermicol-P35 30G treatment as a safe and effective treatment for lip enhancement.
De Boulle
Koen
K
Aalst Dermatology Clinic, Aalst, Belgium. koendeboulle@pandora.be
Swinberghe
Sandra
S
Engman
Marie
M
Shoshani
David
D
D000328:Adult; D000818:Animals; D003094:Collagen / Q000008:administration & dosage* / Q000737:chemistry; D003357:Cosmetic Techniques / Q000009:adverse effects; D003432:Cross-Linking Reagents / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D005782:Gels / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D007279:Injections, Subcutaneous; D008046:Lip / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012189:Retrospective Studies; D012266:Ribose / Q000008:administration & dosage* / Q000737:chemistry; D013552:Swine; D013997:Time Factors; D016896:Treatment Outcome
D003432:Cross-Linking Reagents; D005782:Gels; D012266:Ribose; D003094:Collagen